On the other hand, pioglitazone, SGLT2i, and GLP1 RAs have shown impressive results with improvement of liver fat accumulation and resolution of NASH, rising as promising agents for NAFLD; it is no wonder that pioglitazone is the only drug approved for NASH with concomitant significant liver fibrosis by all major liver societies. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.